TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05492955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker Care Model
Description: Participants will be given a digital BP Cuff and a standardized training on its operation, and assigned a CHW from their local Community Health Team. The participant will be instructed to take 6-10 measurements BP per week and record them in a logbook. CHWs will return to participant homes every 2-4 weeks to collect BP measurements and enter them into a data collection system, assess for symptoms, and discuss treatment adherence and lifestyle recommendations. BP readings will be brought by the CHW to their assigned nursing supervisors at their local clinic, who will initiate and tailor medications based on a standardized clinical decision support algorithm, based on SA DoH hypertension control guidelines. All treatment decisions will be made by the nursing supervisors. Participants will either obtain medication(s) at the pharmacy or, as possible, have them delivered by a CHW.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Community Health Worker-based with Mobile Health Blood Pressure Monitoring Model
Description: Participants in this arm will also be given a BP Cuff, (but with cellular network capability, such that BP data can be directly transmitted to trial server), given training on its operation, and assigned a CHW from their local Community Health Team. The participant will be instructed to take 6-10 measurements BP per week, which will be automatically uploaded onto the server to be made available by the nurse supervisors. CHWs will return to participant homes every 2-4 weeks to ensure functionality of the devices and transmission, collect BP measurements if the system is not functional, assess for symptoms, and discuss treatment adherence and lifestyle recommendations. Nursing supervisors at the clinic will use the remotely collected BP data to initiate and tailor medications based on the same standardized clinical decision support (CDS) algorithm, based on SA DoH hypertension control guidelines. All treatment decisions will be made by the nursing supervisors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Model
Description: Participants in the SOC arm will be referred to their clinic for active care as per standard clinical protocols. All care will be provided at the clinic. Routine care consists of regular visits to the clinic until BP is under control (\<140/90 mmHg) and then at 6 monthly intervals. BP measurements to guide management decisions will be made at the clinic using standard clinic equipment. Symptoms related to hypertension and/or medications will be assessed at each visit. Medications available will include medications on the South African Essential Drug list and which are available in the pharmacy. Prescriptions are picked up at the clinic pharmacy by patients as per routine protocol at the clinics. CHWs may also conduct monitoring as guided by clinical guidelines and as advised by their clinical supervisors during the study period to assess for adherence and provide education.
Study: NCT06251973

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AgenT-797
Description: AgenT-797 is an investigational product, composed of allogeneic human unmodified iNKT cells, isolated from mononuclear cell aphaeresis units from healthy donors

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: Botensilimab is a novel, human, Fc-engineered IgG1 anti-CTLA-4 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Botensilimab is supplied as a sterile, single-use solution for IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab is a fully human anti-VEGFR2 monoclonal IgG1 antibody (IgG1) that binds with high affinity to the extracellular domain of VEGFR2. Ramucirumab is a part of standard of care treatment for advanced gastric cancer or GEJ adenocarcinoma, after prior treatment with fluoropyrimidine- or platinum-containing chemotherarapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is widely used across multiple cancer types and is a part of standard of care treatment for advanced EG adenocarcinoma after prior treatment with fluoropyrimidine- or platinum-containing chemotherarapy.
Study: NCT05601700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole tablets
Description: ATC: L02BG04

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin AUC 5 and paclitaxel 175 mg/m2
Description: ATC: L01XA02 and ATC: L01CD01 respectively
Study: NCT05614739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-435
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-435
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-435
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-435
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-435
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-435
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV
Study: NCT05365061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: periosteal electrical dry needling with no maintenance treatments
Description: periosteal electrical dry needling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: periosteal electrical dry needling with maintenance treatments every other month
Description: periosteal electrical dry needling with maintenance treatments every other month

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: periosteal electrical dry needling with monthly maintenance treatments
Description: periosteal electrical dry needling with monthly maintenance treatments
Study: NCT05538065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up booster Alert
Description: Once the order entry or open encounter alert displays, the provider will have the option to schedule a follow-up message that will be sent 4 weeks after the alert is triggered

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-commitment
Description: A two-staged pre-commitment electronic health record alert will be used. In the 1st alert, the providers will be prompted to discuss risks of these high-risk medications and share a handout about the risks with their patients, at their own discretion. The second alert will be either an order entry or open encounter alert, depending on the arm the provider is assigned to.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Alert
Description: An enhanced alert (known as a Best Practice Advisory \[BPA\]) will appear on the provider's electronic health record screen and will contain several standard components such as information about why the medication is dangerous for their patient and an order set that will allow providers to order a gradual dose taper for their patient, order alternative medications, place a referral to a behavioral health specialist, provide instructions on how to make lifestyle modifications to improve patient symptoms, and add patient instructions for how to gradually taper off benzodiazepines and sedative hypnotics, as applicable.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Alert
Description: An enhanced alert (known as a Best Practice Advisory \[BPA\]) will appear on the provider's electronic health record screen and will contain several standard components such as information about why the medication is dangerous for their patient and an order set that will allow providers to order a gradual dose taper for their patient, order alternative medications, place a referral to a behavioral health specialist, provide instructions on how to make lifestyle modifications to improve patient symptoms, and add patient instructions for how to gradually taper off benzodiazepines and sedative hypnotics, as applicable.
Study: NCT06236984

Intervention type: OTHER
Intervention: multiFiltratePRO with all CKRT treatment modes
Description: Retrospective Data Analysis of CKRT treatments in adult mode with multiFiltratePRO
Study: NCT05792085

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EHR-based GDMT Optimization
Description: Patients will be prescribed appropriate GDMT for HFrEF if they meet clinical criteria by the study team, appropriate lab work and follow up testing will be sent and followed up by the team. All recommendations and plans will be copied to primary care providers who can opt out if disagree, but also to improve telementoring to build clinical comfort.
Study: NCT06090305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: levidex
Description: Participants will receive access to the digital health application levidex in addition to treatment as usual (TAU).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will receive access to an overview of relevant brochures from the Deutsche Multiple Sklerose Gesellschaft (German Multiple Sclerosis Society) on the topic of lifestyle in MS in addition to treatment as usual (TAU).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual (TAU)
Description: treatment as usual (TAU)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment as usual (TAU)
Description: treatment as usual (TAU)
Study: NCT05552326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olezarsen
Description: Olezarsen will be administered by SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olezarsen-matching placebo will be administered by SC injection.
Study: NCT06506448

Intervention type: DIAGNOSTIC_TEST
Intervention: CT Coronary Angiography
Description: CTCA for anatomical, physiological, plaque composition and inflammatory assessment of coronary arteries
Study: NCT06344481

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical (Hyalex Cartilage Knee Implant)
Description: Implantation of Hyalex Cartilage Knee Implant.
Study: NCT05669664

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given IM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05010421

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol 0.05% Emollient Top Cream
Description: Topical corticosteroid treatment of affected vulvar skin areas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-ablative CO2 Laser
Description: Superficial non-ablative laser treatment of affected vulvar skin areas.
Study: NCT05742906

Intervention type: DEVICE
Group type: OTHER
Intervention: Tricuspid valve replacement with the Cor TRICUSPID ECM Valve
Description: Tricuspid valve replacement with the Cor TRICUSPID ECM Valve for the surgical management of tricuspid valve disease or dysfunction.

Intervention type: DEVICE
Group type: OTHER
Intervention: Tricuspid valve replacement with the Cor TRICUSPID ECM Valve
Description: Tricuspid valve replacement with the Cor TRICUSPID ECM Valve for the surgical management of tricuspid valve disease or dysfunction.
Study: NCT06314724

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella Vaccine
Description: lyophilized powder,subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varivax
Description: lyophilized powder,subcutaneous injection
Study: NCT05125679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered by subcutaneous injection.
Study: NCT06649097

Intervention type: DEVICE
Intervention: IRRAflow® CNS (Active Fluid Exchange) System
Description: The IRRAflow system offers automated irrigation, controlled drainage and intracranial pressure (ICP) monitoring all in one system. It consists of three main parts - IRRAflow 2.0 Catheter, IRRAflow Tube Set, IRRAflow Control Unit.
Study: NCT05742906

Intervention type: DEVICE
Group type: OTHER
Intervention: Tricuspid valve replacement with the Cor TRICUSPID ECM Valve
Description: Tricuspid valve replacement with the Cor TRICUSPID ECM Valve for the surgical management of tricuspid valve disease or dysfunction.
Study: NCT06648239

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: In the usual care group, patients will proceed directly to ICA following referral from community cardiology, as is the current standard of care. Research staff will screen participants in this group for significant CAD using the decision support tool; however, the tool's recommendations will not affect their care, as all patients in this group will invariably receive ICA.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Centralized triage with risk score-based screening for obstructive CAD
Description: Patients randomized to the intervention will have selected features of their medical history, recorded on their referral form, entered into a decision support tool by research personnel to generate a recommendation of whether they should proceed directly to ICA or whether they should receive CCTA. Patients with recommendations for ICA will proceed directly to ICA. Patients with recommendations for CCTA will be referred to CCTA. Based on the results of the CCTA, recommendations for medical management versus referral for ICA will be made.
Study: NCT06648824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral syrup
Study: NCT06129539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 4326
Description: Administered as an intramuscular (IM) injection
Study: NCT05695261

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Microbial Transplantation Therapy
Description: Subjects randomized to the MTT/antibiotic arm will be administered oral MTT capsules over the course of 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: Subjects randomized to the MTT/antibiotic arm will receive oral antibiotics for 7 days prior to the MTT administration visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (in place of MTT)
Description: Subjects randomized to the placebo arm will be administered oral placebo capsules in place of MTT over the course of 28 days.
Study: NCT05718557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PYX-106
Description: Intravenous (IV) infusion
Study: NCT05299658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNMAu8
Description: CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bi-pyramid, tetrahedron, decahedron, planar spheroids). Those choosing to participate in the OLE period will orally receive 30 mg of CNM-Au8, once daily.
Study: NCT05219396

Intervention type: DEVICE
Intervention: Knee arthroplasty
Description: Your knee should be replaced with mobile bearing (MB), medial congruent (MC) and posterior stabilized (PS) design protheses.

Intervention type: DEVICE
Intervention: Knee arthroplasty
Description: Your knee should be replaced with mobile bearing (MB), medial congruent (MC) and posterior stabilized (PS) design protheses.

Intervention type: DEVICE
Intervention: Knee arthroplasty
Description: Your knee should be replaced with mobile bearing (MB), medial congruent (MC) and posterior stabilized (PS) design protheses.
Study: NCT05819346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle
Description: Participants assigned to the intervention group receive access to a lifestyle mobile application for three months after rehabilitation or treatment has finished. The digital program is target group-specific and includes personalization and interactive elements without face-to-face appointments during the intervention. One virtual appointment at the beginning of the intervention with the study staff ensures that participants familiarize themselves with the mobile application and that they are assigned to a suitable program level. The intervention is mainly based on the following behavior change technique (BCT) clusters: goals and planning, feedback and monitoring, shaping knowledge, and comparison of behavior.
Study: NCT06217393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itopride Hydrochloride 150 mg extended release tablets
Description: The intervention in the study is in form of test and active control groups- see details below • Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals (preferably the same meal throughout the treatment)~• Active Control group - Itopride Hydrochloride 50 mg film coated tablets 3 times daily before meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itopride Hydrochloride 50 mg film coated tablets
Description: The intervention in the study is in form of test and active control groups- see details below • Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals (preferably the same meal throughout the treatment)~• Active Control group - Itopride Hydrochloride 50 mg film coated tablets 3 times daily before meals
Study: NCT04646096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAKO THA 4.0 System
Description: Measure how the accuracy and precision of robotic arm-assisted total hip arthroplasty (THA) for placement accuracy of implant position in both the anterior and posterior approach.. The intervention will assess the precision of the MAKO system in placing hip components according to plan. It will compare hip angles executed by the Mako system intraoperatively with the 'gold standard' of 3D computer tomography (CT) scans.~The postoperative CT scan can show the precision of the MAKO system by accurately determining the location of hip replacements in patients after surgery.
Study: NCT06454708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clascoterone Cream 1%
Description: Clascoterone Cream 1% (Winlevi) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
Study: NCT05691504

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study: NCT05695261

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (in place of antibiotics)
Description: Subjects randomized to the placebo arm will receive oral placebo in place of antibiotics for 7 days prior to the MTT administration visit.
Study: NCT05716178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal health education
Description: The local religious leaders from each clustered kebele will be recruited based on religious educational status (educational status greater than or equal to diploma), acceptance by their followers and popularity, in collaboration with religious organization leaders, health extension workers, and kebele leaders. Then after the potential religious leaders are recruited, the two days training will be given for them. Recruited religious leaders are expected to give training on the topics (maternal health) for four sessions to promote healthy maternal behaviors for the members of their religion.
Study: NCT05406219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2395840
Description: Immediate release (IR) tablet, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2395840
Description: Immediate release (IR) tablet, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2395840
Description: Immediate release (IR) tablet, oral administration
Study: NCT05613452

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon ion beam radiotherapy
Description: Patients receive carbon ion radiotherapy of 12GyE per fraction, totally 4 fractions. Patients with tumors ≥4cm should receive at least 4 cycles of platinum-based doublet chemotherapy.
Study: NCT05691504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelcitoclax
Description: Given IV
Study: NCT06322745

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture renorrhaphy only for hemostasis of the tumor bed in laparoscopic partial nephrectomy
Description: Suture renorrhaphy will be used in 2 layers; medullary and cortical, with Vicry 2/0 or 3/0 and secured with V-lock. Early unclamping will be done after hemostasis of the medullary layer. Renorrhaphy of the cortical layer will be continued after that.
Study: NCT05098184

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocyte
Description: Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
Study: NCT06192758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraSphere PCa
Description: Single session treatment of TheraSphere PCa - Yttrium-90 Glass Microspheres for the treatment of prostate cancer. Dose vials will be available in activity ranging from 0.1 GBq (2.7 mCi) to 3 GBq (81 mCi).
Study: NCT06322745

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thulium beam coagulation and suture renorrhaphy for hemostasis of the tumor bed in laparoscopic partial nephrectomy
Description: A 2-μm continuous thulium laser with 365 μm laser fiber at 30-40 W will be used for coagulation of the tumor bed. Large vessels that may not be completely sealed with thulium beam will be closed by V-lock to achieve safe and stable hemostasis. Early unclamping will be done after hemostasis of the tumor bed. Suture renorrhaphy will be used in 1 layer to approximate the renal parenchyma.